- Conditions
- Neuroblastoma
- Interventions
- filgrastim, carboplatin, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2497–2520
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ventricular Septal Defect
- Interventions
- Clear priming of the bypass pump
- Procedure
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Month to 18 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, docetaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Solid Cancer
- Interventions
- R-DXd, Paclitaxel, Topotecan, PLD
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 45
- States / cities
- Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more
- Conditions
- HIV Infections, H1N1 Influenza Virus
- Interventions
- Influenza A (H1N1) monovalent vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 29
- States / cities
- Alhambra, California • La Jolla, California • Long Beach, California + 22 more
- Conditions
- Hepatitis C
- Interventions
- TMC435, TVR
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 771 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 32
- States / cities
- Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, BMS-986205, BMS-813160
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
- Conditions
- Smart Eyewear
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Osteosarcoma
- Interventions
- Azenosertib, Gemcitabine
- Drug
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Oakland, California • Santa Monica, California + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], Copegus
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
- Conditions
- Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Interventions
- Fish oil (eicosapentaenoic acid and docosahexanoic acid)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
- Conditions
- Pregnancy, Effective Contraceptive Use, Family Planning
- Interventions
- Enhanced NFP Care
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 45 Years · Female only
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Olympia, Washington • Seattle, Washington • Vancouver, Washington
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- DISC-1459
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
- Interventions
- Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Nivolumab, Patient Observation, Positron Emission Tomography
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 727
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide(Nubeqa, BAY1841788)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 24
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Worcester, Massachusetts • Kansas City, Missouri + 3 more
- Conditions
- Advanced Melanoma
- Interventions
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
- Conditions
- Reading Disability
- Interventions
- preK
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 60 Months to 72 Months
- Enrollment
- 44 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Very Preterm and Extremely Preterm Birth
- Interventions
- Urine sodium testing, Serum sodium testing, Milk fortification
- Diagnostic Test · Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Portland, Oregon • Seattle, Washington
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 43
- States / cities
- Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
- Conditions
- Leukemia
- Interventions
- Bendamustine
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Orange, California • San Diego, California • St. Petersburg, Florida + 16 more